Updated on 4 June 2014
Novartis' novel cancer drug passes phase II trials
Singapore: Novartis announced the success of a pivotal phase II trial for the investigational oral compound LDE225 (sonidegib). The drug cures advanced metastatic basal cell carcinoma (mBCC) which accounts for more than 80 percent of non-melanoma skin cancers.
The data was revealed in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results demonstrated that patients showed marked tumour shrinkage, after a median follow-up of 13.9 months.
The efficacy and safety of two oral doses of LDE225, 200 mg and 800 mg were assesed in the trail on patients suffering from mBCC. Both the doses showed significant improvement in tumor shrinkage, with a median duration of response time of 8.3 months for patients with mBCC treated with LDE225 800 mg.
Mr Alessandro Riva, managing director, Global Head, Novartis Oncology Development and Medical Affairs stated that, "These results represented an important milestone in the clinical development of LDE225, as well as in our research strategy to develop new therapies for patients with unmet needs." He further added that with approval LDE225 could be a best treatment option for patients with the disease, which could be disfiguring and life threatening in later stages.